Ticker brief
BMRN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
13
authors 14d
10
crowd 14d
+0.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-18 → 2026-08-25 · now +0.45 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | -0.10 |
| @OpenOutcrier | C | · | 1 | -0.10 |
| @FwdQuarter | C | · | 1 | -0.10 |
| @CrweWorld | C | · | 1 | -0.10 |
| @fwpharma | B | +0.98 | 1 | +0.35 |
| @semodough | C | -3.01 | 1 | -0.10 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.15 |
| @FintwitAi | C | +1.14 | 1 | -0.10 |
| @cnfinancewatch | B | -1.92 | 1 | -0.10 |
| @ArtofSpecuycky | B | +0.68 | 1 | +0.45 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-25 | @ArtofSpecuycky | +0.45 | Presents genomics as a major decade-long investment theme and lists representative stocks. | · | tweet ↗ |
| 2026-08-23 | @cnfinancewatch | -0.10 | Reports three acquisitions and a SPAC merger, plus a BMO rating and target for BioMarin. | · | tweet ↗ |
| 2026-08-19 | @FintwitAi | -0.10 | BioMarin is acquiring private Alesta Therapeutics for $275M cash. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | -0.10 | BioMarin's acquisition adds an oral HPP program to its skeletal-disease pipeline. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | -0.10 | BioMarin will acquire Alesta for up to $490 million, adding oral HPP asset ALE1. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | -0.10 | BioMarin's acquisition adds an oral HPP program to its skeletal-disease pipeline. | · | tweet ↗ |
| 2026-08-18 | @AponiaAnalytics | +0.15 | Reports BioMarin's $275 million acquisition of ALE1 while other assets are spun out. | · | tweet ↗ |
| 2026-08-18 | @semodough | -0.10 | BioMarin plans to acquire Alesta for $275 million upfront to gain a Phase 1/2a rare-disease asset. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | -0.10 | Biotech news roundup lists trial, regulatory, acquisition and access catalysts with opening moves. | · | tweet ↗ |
| 2026-08-18 | @fwpharma | +0.35 | Reports BioMarin's Alesta deal adds a potential oral hypophosphatasia therapy. | · | tweet ↗ |
| 2026-08-18 | @CrweWorld | -0.10 | BioMarin announces the acquisition of Alesta Therapeutics and its oral-therapy program. | · | tweet ↗ |
| 2026-08-18 | @FwdQuarter | -0.10 | Reports BMRN acquiring Alesta Therapeutics for $275M upfront plus milestones. | · | tweet ↗ |
| 2026-08-18 | @OpenOutcrier | -0.10 | BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.